Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
University of Nevada, Las Vegas · Lou Ruvo Brain Institute
Abstract
)-have been approved in the USA for the treatment of Alzheimer's disease (AD). Anti-amyloid monoclonal antibodies are the first disease-modifying therapies for AD that achieve slowing of clinical decline by intervening in the basic biological processes of the disease. These are breakthrough agents that can slow the inevitable progression of AD into more severe cognitive impairment. The results of trials of anti-amyloid MABs support the amyloid hypothesis and amyloid as a target for AD drug development. The success of MABs reflects a relentless application of neuroscience knowledge to solving major challenges facing humankind. The success of these transformative agents will foster the development of more…
Citation impact
- FWCI
- 40.31
- Percentile
- 100%
- References
- 55
Authors
1Topics & keywords
- Medicine
- Monoclonal antibody
- Disease
- Amyloid (mycology)
- Transformative learning
- Immunology
- Pharmacology
- Antibody
Funding
- ADAlzheimer's Drug Discovery FoundationAward: P20GM109025
- NINational Institute on AgingAwards: P20GM109025, P30AG072959, R35AG71476, P20AG068053, R01AG053798
- NINational Institute of General Medical SciencesAwards: P20AG068053, P20GM109025
- NINational Institute of Neurological Disorders and StrokeAward: U01NS093334